Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Local Steroid Injection in the Treatment of Idiopathic Carpal Tunnel Syndrome: A Randomized Double-blind Placebo-controlled Trial Among Patients Planned for Surgical Treatment
Brief Summary: The aim of this study is to assess the efficacy of injecting steroid into the carpal tunnel in relieving symptoms of carpal tunnel syndrome for at least 1 year with outcomes measured with patient evaluated symptoms score.Out of the patients referred by primary care, those with a clinical diagnosis of CTS who have tried wrist splint and whose symptom severity is judged by the examining surgeon to warrant surgery are offered to be put on the waiting list for carpal tunnel release. This means a waiting time of approximately 3 months. Patients who give informed consent will be asked to attend the outpatient clinic for a physical examination followed by allocation to one of the three trial groups. Immediately following the allocation the patients will receive the assigned treatment.


Options:
A: Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: Tocilizumab + Placebo Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo MTX, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: Methotrexate + Placebo Tocilizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: placebo TCZ | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Methotrexate + Placebo Tocilizumab, Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: placebo MTX; Assigned to Arm(s): Tocilizumab + Placebo Methotrexate | Intervention Type: DRUG; Name: placebo TCZ; Assigned to Arm(s): Methotrexate + Placebo Tocilizumab | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): Tocilizumab + Methotrexate, Tocilizumab + Placebo Methotrexate
B: Arm Label: Methylprednisolone 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone 80 mg | Arm Label: Methylprednisolone 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone 40 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline | Intervention Type: DRUG; Name: Methylprednisolone 80 mg; Assigned to Arm(s): Methylprednisolone 80 mg | Intervention Type: DRUG; Name: Methylprednisolone 40 mg; Assigned to Arm(s): Methylprednisolone 40 mg | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone 40 mg | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone 80 mg | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium chloride | Intervention Type: DRUG; Name: Methylprednisolone 40 mg; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methylprednisolone 80 mg; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Sodium chloride; Assigned to Arm(s): C
D: Arm Label: Conservative group; Type: EXPERIMENTAL; Interventions: Other: Conservative group | Arm Label: Surgical group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical group | Intervention Type: OTHER; Name: Conservative group; Assigned to Arm(s): Conservative group | Intervention Type: PROCEDURE; Name: Surgical group; Assigned to Arm(s): Surgical group

Answer: C